The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IMM2510, an anti-PD-L1/VEGF bispecific antibody fusion protein, in patients with R/R STS: A phase Ib expansion study.
 
Haiyan Xu
No Relationships to Disclose
 
Shegan Gao
No Relationships to Disclose
 
Ruinuo Jia
No Relationships to Disclose
 
Weifeng Liu
No Relationships to Disclose
 
Zhen Huang
No Relationships to Disclose
 
Bin Li
No Relationships to Disclose
 
Jian Zhang
No Relationships to Disclose
 
Wang Ma
No Relationships to Disclose
 
Suxia Luo
No Relationships to Disclose
 
Weitao Yao
No Relationships to Disclose
 
Binghao Li
No Relationships to Disclose
 
Xiangdong Cheng
No Relationships to Disclose
 
Zhengbo Song
No Relationships to Disclose
 
Xi Xi Wu
No Relationships to Disclose
 
Hao Pang
Employment - ImmuneOnco Biopharmaceuticals(Shanghai) Inc.
 
Deqiang Jing
Employment - ImmuneOnco Biopharmaceuticals(Shanghai) Inc.
 
Liyun Yang
Employment - ImmuneOnco Biopharmaceuticals(Shanghai) Inc.
 
Qiying Lu
Employment - ImmuneOnco Biopharmaceuticals(Shanghai) Inc.
Leadership - ImmuneOnco Biopharmaceuticals(Shanghai) Inc.
 
Wenzhi Tian
Leadership - ImmuneOnco Biopharmaceuticals(Shanghai) Inc.
Stock and Other Ownership Interests - ImmuneOnco Biopharmaceuticals(Shanghai) Inc.
 
Xichun Hu
Honoraria - AstraZeneca; Daiichi Sankyo/Lilly; Eisai; Hengrui Pharmaceutical; Lilly; Merck; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca